© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
.png?w=600&fit=crop&auto=format)
November 14, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
November 01, 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
June 30, 2021
FDA approval of teprotumumab as therapeutic offers hope for patients.
April 14, 2021
Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.
April 02, 2021
Study highlights role of demographic and socioeconomic characteristics in treatment.
March 02, 2021
Autologous serum eye drops and blood products offer hope to patients.
January 27, 2021
Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.
November 16, 2020
Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population
November 13, 2020
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.
October 18, 2020
Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.